Why Diversity in Diabetes Clinical Trials Matters

Clinical trials are the engine of medical progress, generating the evidence necessary to develop safe and effective treatments for diabetes. Every new medication, device, or lifestyle intervention that reaches patients has been tested through rigorous studies. Yet a persistent and deeply troubling gap remains: minority patients—Black, Hispanic, Indigenous, Asian, and other populations—are significantly underrepresented in these trials. This lack of diversity has direct, measurable consequences. Treatments may be less effective or even harmful for certain groups because genetic, metabolic, and social factors vary across populations. When minority voices are absent from research, the data that guide clinical decisions fail to reflect the real diversity of diabetes patients, perpetuating health disparities that have plagued the nation for decades.

Diabetes does not affect all communities equally. Black and Hispanic adults are nearly twice as likely to be diagnosed with diabetes as non-Hispanic white adults, and they experience higher rates of complications such as kidney failure, amputation, and blindness. Indigenous populations face some of the highest prevalence rates in the world. Yet these same groups are far less likely to enroll in clinical trials. The paradox demands urgent attention. By exploring the root causes of low participation and implementing targeted strategies, researchers, healthcare providers, and policymakers can build a more inclusive research ecosystem that yields better outcomes for everyone.

The Impact of Underrepresentation on Diabetes Care

The consequences of low minority participation in diabetes trials extend beyond academic statistics. When trial populations are predominantly white, findings may not apply to other groups. For example, certain diabetes medications work differently in Black patients due to variations in drug metabolism and insulin sensitivity. GLP-1 receptor agonists and SGLT2 inhibitors have shown differential efficacy and side-effect profiles across ethnic groups. Without adequate representation, clinicians are left guessing whether a treatment proven in a homogeneous sample will work in their diverse patient panels. This evidence gap contributes to suboptimal outcomes and undermines efforts to achieve health equity.

Moreover, underrepresentation hinders the development of therapies tailored to specific populations. Diabetes in minority communities is often compounded by higher rates of comorbidities such as hypertension, obesity, and chronic kidney disease—conditions that themselves are understudied in diverse groups. The lack of inclusive data slows progress toward personalized medicine, leaving minority patients with fewer targeted options. The urgency is clear: improving diversity in clinical trials is not just a moral imperative but a scientific necessity.

Common Barriers Faced by Minority Patients

The obstacles to clinical trial participation are multifaceted, spanning historical trauma, structural inequities, cultural dynamics, and practical hurdles. Below, each major barrier is examined in depth, with an emphasis on how they specifically affect diabetes care.

1. Lack of Trust: A Legacy of Historical Abuses

Perhaps the most formidable barrier is a deep-seated mistrust of the medical establishment, rooted in centuries of exploitation and discrimination. Landmark injustices such as the Tuskegee Syphilis Study—where Black men with syphilis were denied treatment for decades without their knowledge—have left an indelible scar. More recent events—such as reports of involuntary sterilizations of Indigenous women, unethical experimentation on prisoners, and the under-treatment of pain in Black patients—reinforce the perception that research systems cannot be trusted. For minority patients with diabetes, this historical baggage translates into fear that participation may lead to harm, neglect, or exploitation. Trust is not easily rebuilt; it requires transparent communication, community partnership, and a demonstrated commitment to ethical practices.

Diabetes-specific concerns amplify this distrust. Patients may fear that experimental treatments might worsen their blood sugar control or that researchers will abandon them after the study ends. Stories of genetic research being used to stigmatize communities—such as the Havasupai Tribe case, where blood samples were used for purposes beyond the original consent—further erode confidence. Rebuilding trust must be central to any strategy to increase diversity.

2. Limited Awareness and Inadequate Outreach

Many minority patients simply do not know that clinical trials exist or how to access them. Traditional recruitment methods—physician referrals, online registries, advertisements in medical journals—often fail to reach diverse audiences. Information about trials may be disseminated through channels not trusted by minority communities, such as mainstream media or research hospital websites. Furthermore, educational materials about the purpose, process, and potential benefits of clinical trials are often written in dense, technical language. Low health literacy around research participation compounds the problem, leaving patients unaware that they have options beyond standard care.

For diabetes patients, who already must navigate complex self-management regimens, adding the burden of learning about clinical trials can feel overwhelming. Outreach must meet people where they are—in churches, community centers, barbershops, and diabetes support groups—using plain language and culturally relevant messengers.

3. Language and Communication Barriers

For non-English-speaking patients or those with limited English proficiency, navigating the clinical trial process can be overwhelming. Consent forms, study protocols, and follow-up instructions are predominantly available only in English. Even when translations exist, they may not capture nuanced medical terminology, leading to confusion about risks, benefits, or the patient's role. Bilingual staff and interpreters are often in short supply, especially in research settings. This communication gap not only deters enrollment but also compromises informed consent—a cornerstone of ethical research. Without clear, culturally appropriate communication, minority patients may feel excluded or coerced.

In diabetes trials, where instructions often involve dietary changes, medication adjustments, or frequent glucose monitoring, precise communication is critical. A misunderstanding could lead to dangerous health consequences. Researchers must invest in robust language support, including translated materials and real-time interpretation services.

4. Financial and Logistical Burdens

Participating in a clinical trial often requires time and money that many minority patients cannot afford. Costs may include transportation to and from the trial site, parking fees, lost wages from taking time off work, childcare or eldercare expenses, and even lodging for multi-day visits. While some trials reimburse these expenses, the reimbursement process is often slow, incomplete, or poorly communicated. Minority patients are more likely to have jobs with inflexible schedules or hourly wages, making it difficult to attend frequent study visits. For those managing a chronic condition like diabetes—which already demands regular appointments, medication costs, and glucose monitoring supplies—the additional burden of trial participation can be prohibitive.

Diabetes trials often require fasting blood draws, multiple clinic visits, or continuous glucose monitor insertions. Even modest out-of-pocket costs can derail participation. Studies that offer upfront stipends, provide transportation services, or allow remote data collection have seen higher minority enrollment.

5. Cultural Beliefs and Practices

Cultural attitudes toward health, illness, and medical intervention can shape a patient's willingness to enroll in a trial. Some communities place a strong emphasis on holistic or traditional medicine, viewing clinical research as unnatural or invasive. Others may hold religious beliefs that conflict with certain study procedures, such as fasting for glucose tests or taking experimental medications. Furthermore, cultural norms around decision-making can influence participation: in some families, health decisions are made collectively rather than individually, requiring the buy-in of elders or community leaders. Researchers who fail to recognize and respect these cultural dynamics may inadvertently alienate potential participants.

For example, among some Hispanic groups, the concept of familismo emphasizes family involvement in health decisions. A trial that expects individual enrollment without family discussion may be viewed as disrespectful. Similarly, some Indigenous communities hold that health is a balance between physical, spiritual, and community wellbeing—research that focuses only on biological markers may seem incomplete. Culturally competent research design must account for such perspectives.

6. Structural Racism and Healthcare Access

Systemic inequities in healthcare delivery create additional barriers. Minority patients are more likely to receive care in under-resourced clinics or hospitals that lack the infrastructure to conduct clinical trials. Primary care physicians serving minority populations may not be aware of trial opportunities or may not be included in research networks. Even when trials are available, sites are often located in academic medical centers far from the communities where minority patients live and receive care. This geographical and institutional disconnect makes participation a logistical impossibility for many.

Implicit bias among healthcare providers can also lower trial referral rates for minority patients. Studies show that clinicians are less likely to discuss clinical trials with Black and Hispanic patients, based on assumptions about their adherence, interest, or eligibility. Diabetes providers may assume that patients struggling with glycemic control are too unstable for a trial, without considering that they might benefit most from new interventions. This gatekeeping perpetuates underrepresentation.

7. Fear of Side Effects and Unfamiliar Treatments

For many minority patients, the prospect of receiving a placebo or an unproven intervention is unsettling. Diabetes management often requires precise control of blood glucose, and patients may worry that participation in a trial could destabilize their health. Stories of experimental drugs causing severe side effects in diverse populations—such as the higher rates of diabetic ketoacidosis with SGLT2 inhibitors in Black patients—amplify these fears. Without clear, reassuring explanations of how patient safety is protected (data safety monitoring boards, informed consent, ability to withdraw), many choose to stay with established treatments and familiar providers.

The placebo effect is often misunderstood. Patients may fear being assigned to a placebo group and receiving no treatment for their diabetes. In reality, most diabetes trials are designed to add experimental therapies on top of standard care, so all participants receive at least baseline treatment. But this nuance is rarely communicated effectively.

Strategies to Overcome Barriers and Increase Participation

Addressing these barriers requires a comprehensive, multi-pronged approach that centers on trust, accessibility, and cultural humility. Below are evidence-based strategies that researchers, institutions, and policymakers can adopt.

1. Build Genuine Community Partnerships

Effective outreach begins with relationship-building. Researchers should collaborate with trusted community organizations—churches, community health centers, diabetes support groups, and local chapters of minority health advocates. These organizations can serve as bridges, providing cultural insight and facilitating communication. Community advisory boards that include patient representatives can guide study design, recruitment materials, and consent processes. When communities see that research is being conducted with them rather than on them, trust begins to grow.

Examples include the All of Us Research Program, which has established partnerships with hundreds of community organizations to engage underrepresented groups. For diabetes trials, partnering with federally qualified health centers (FQHCs) that serve majority-minority populations can be particularly effective.

2. Invest in Culturally and Linguistically Appropriate Education

Educational materials must be translated into the languages spoken by target populations and adapted to appropriate reading levels. Visual aids, videos, and storytelling can make complex concepts more relatable. Information should clarify the voluntary nature of participation, the distinction between standard care and experimental treatment, and the protections in place for participants. Offering educational sessions at convenient times and locations—during existing diabetes classes, community fairs, or virtual webinars—can increase awareness without adding burden. Peer educators from the same ethnic or cultural background can be especially effective in addressing concerns and modeling positive attitudes toward research.

For instance, the National Institute of Diabetes and Digestive and Kidney Diseases provides plain-language guides on clinical trials. Using such resources can demystify the process.

3. Provide Robust Language Support

At a minimum, consent forms and key study documents should be available in the most common languages of the target population. But written translation alone is not enough. Trained medical interpreters should be available for all interactions, from initial discussions to follow-up visits. Research staff should be proficient in cultural sensitivity and communication skills, learning to listen to patients' concerns without judgment. Using standardized communication protocols that emphasize plain language and teach-back methods can ensure that patients truly understand what they are agreeing to.

Telehealth platforms with built-in interpretation services can help bridge gaps, especially for diabetes trials that involve remote monitoring. Studies that invest in language access see higher enrollment and retention among non-English-speaking participants.

4. Reduce Financial and Logistical Barriers

Study budgets should account for realistic reimbursement of participant expenses, including transportation, lodging, and lost wages. Reimbursement processes should be streamlined—ideally providing cash or prepaid cards at the time of visits rather than weeks later. Offering flexible scheduling, including evening and weekend appointments, can accommodate working patients. Some trials have successfully used mobile research units or partnered with community clinics to bring study visits closer to participants' homes. Telehealth options for follow-up visits can further reduce travel burdens, particularly for diabetes trials that rely on remote glucose monitoring or digital health tools.

The FDA's guidance on clinical trial diversity encourages sponsors to adopt decentralized approaches. Moving forward, reimbursement and logistical support should be standard, not exceptional.

5. Train Research Teams in Cultural Competence and Humility

Beyond mere awareness, cultural humility involves an ongoing commitment to self-reflection and power balancing. Research teams should receive training on the historical context of medical distrust, unconscious bias, and culturally appropriate communication. This training should be reinforced regularly and integrated into study procedures. Culturally competent staff are better equipped to build rapport, address patient concerns effectively, and adapt protocols to meet the needs of diverse populations. Including researchers and staff from minority backgrounds within the study team can also enhance credibility and comfort.

Several organizations offer training modules, such as the CDC's Health Equity Guiding Principles. Making such training mandatory for all research personnel is a key step toward institutional change.

6. Improve Access Through Decentralized and Community-Based Trial Models

Moving away from exclusive reliance on academic medical centers is critical. Decentralized clinical trials (DCTs) leverage technology and local resources to bring research into patients' communities. This can include home visits, remote data collection via smartphones or wearable devices, and partnerships with local pharmacies or primary care clinics. For diabetes trials, continuous glucose monitors and telehealth platforms make it feasible to conduct studies with minimal in-person visits. By embedding trials in familiar, accessible settings, researchers can dramatically increase participation among populations who would otherwise be excluded.

Community-based participatory research (CBPR) models have shown success in Indigenous and rural communities. Involving community health workers as trial liaisons can improve recruitment and retention while building local capacity.

7. Transparently Address Historical Injustices and Build Accountability

Acknowledging past wrongs is a powerful step toward rebuilding trust. Research institutions should publicly commit to ethical practices, share data on their own diversity metrics, and create mechanisms for participant feedback and grievance redress. Establishing independent community oversight boards can provide ongoing accountability. Simple gestures—such as opening meetings with a land acknowledgment or recognizing the contributions of minority participants—can signal a genuine shift in culture. Trust is built incrementally, through consistent actions that demonstrate respect and reciprocity.

Some institutions have begun to publish annual diversity reports on clinical trial enrollment. Transparency encourages accountability and allows the community to track progress.

Innovative Solutions and Emerging Models

Beyond the foundational strategies above, innovative approaches are gaining traction. Digital platforms that match patients to trials based on their demographics and medical history can reduce awareness gaps. Gamification and incentive programs tailored to community values can boost engagement. Pragmatic trials embedded within healthcare systems, such as electronic health record-based recruitment, can reduce bias in referral patterns.

For diabetes specifically, studies like the Look AHEAD trial demonstrated that intentional recruitment efforts—including bilingual materials and flexible scheduling—can achieve diverse enrollment. The Diabetes Prevention Program (DPP) outcome study actively recruited minority participants by offering translation services and culturally tailored content, yielding groundbreaking insights on weight management across ethnic groups. These examples prove that inclusion is possible when resources are allocated appropriately.

Conclusion: A Call to Action

Minority patients with diabetes face a web of interconnected barriers—historical, financial, cultural, and structural—that systematically exclude them from clinical trials. The consequences are not abstract; they play out in persistent health disparities and evidence gaps that undermine the care of millions. Overcoming these barriers will require sustained commitment from funders, researchers, healthcare systems, and communities. It will demand investment in trust-building, language access, financial support, and culturally competent research design. But the returns are invaluable: more generalizable data, more effective treatments, and a healthcare system that truly serves all people.

The time for half-measures is over. Researchers and practitioners must act deliberately, collaboratively, and with urgency to ensure that the promise of clinical research extends equitably to every patient. Comprehensive resources are available through the FDA's clinical trial guide, the NIDDK diabetes trials page, and the CDC's diversity discussion. Community organizations such as the American Diabetes Association also offer advocacy and participation resources. The path forward demands action—not just from researchers, but from every stakeholder committed to health equity.